Penicillin Use in Meningococcal Disease Management: Active Bacterial Core Surveillance Sites, 2009

Abstract

In 2009, in the Active Bacterial Core surveillance sites, penicillin was not commonly used to treat meningococcal disease. This is likely because of inconsistent availability of antimicrobial susceptibility testing and ease of use of third-generation cephalosporins. Consideration of current practices may inform future meningococcal disease management guidelines.

Primer caso de infección por Neisseria meningitidis con susceptibilidad reducida a cefalosporinas de tercera generación reportado en Costa Rica.

“…Una vez que se realiza el diagnóstico de meningitis bacteriana, se debe iniciar tratamiento antibiótico de manera temprana (2). Históricamente, la penicilina se ha utili-zado como tratamiento de elección para la meningitis por meningococo confirmado por laboratorio (3). Sin embargo, en los últimos años se ha visto que la penicilina ha sido menos eficiente para tratar enfermedad por meningococo debido a menor susceptibilidad por parte de la bacteria a dicho antibiótico (2).…”

Detection of Ciprofloxacin-Resistant, β-Lactamase–Producing Neisseria meningitidis Serogroup Y Isolates — United States, 2019–2020

“…Resistance to ciprofloxacin is also uncommon in the United States with only one identified cluster of three ciprofloxacin-resistant cases during 2007-2008 and infrequent sporadic cases (5,7,8). Because N. meningitidis is typically susceptible to clinically relevant antibiotics in the United States, antimicrobial susceptibility testing is not routinely performed on meningococcal isolates (9).…”